The Corporal Michael J. Crescenz VA Medical Center s (CMCVAMC) Nuclear Medicine department requires a licensed vendor by the Nuclear Regulatory Commission to provide the radiopharmaceutical drug Axumin (Fluciclovine F 18 Injection) and calibration sources. This radiopharmaceutical drug is required for a new imaging procedure that will be offered to Veterans. The Calibration sources are required for equipment quality control testing. Axumin injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment. This item is to be delivered directly to the Diagnostic Imaging section of Nuclear Medicine (secured receiving areas), room 3A101B, Philadelphia Veterans Administration Medical Center, Department of Veterans Affairs, 3900 Woodland Avenue, Philadelphia, Pennsylvania 19104.

Bid Protests Not Available